Cycloserine
General Information
Restricted formulary antimicrobial: For details see OUH netFormulary
For all information regarding contra-indications, interactions, contraception, pregnancy and breastfeeding and additional information, see BNF and Summary of Product Characteristics (SPC).
Standard dose
|
Indication |
Oral dose |
|
Tuberculosis resistant to first-line drugs |
See Tuberculosis section |
Renal and hepatic impairment
Renal impairment
| Creatinine Clearance (mL/min) | Oral Dose |
| 50 and over | Dose as in normal renal function |
| 10-50 | 250mg-500mg every 24 hours. Monitor blood levels weekly. |
| Less than 10 | 250mg-500mg every 36-48 hours. Monitor blood levels weekly. |
| HD/HDF/High Flux |
Dialysed; give after dialysis Dose as in creatinine clearance less than 10mL/min or 500mg three times a week after dialysis. |
| PD |
Unknown dialysability Dose as in creatinine clearance less than 10mL/min. |
Note: dose ranges use creatinine clearance, rather than eGFR.
Hepatic impairment
No dose adjustment required but monitor hepatic function during treatment.
Additional information
Cycloserine levels should be monitored in all patients, especially in those with renal impairment or if dose exceeds 500 mg daily or if signs of toxicity. See Cycloserine - TB DRUG MONOGRAPHS for more information.
References
- . Neon Healthcare Ltd. Cycloserine 250mg Hard capsules summary of product characteristics. Electronic medicines compendium. Last revision of the text 15/3/23. Accessed via www.medicines.org.uk Accessed 25/9/26.
- British National Formulary. Cycloserine. BNF online accessed via www.medicinescomplete.com Accessed 25/9/26.
- The Renal Drug Database. Cycloserine. Last updated 28/10/24. Accessed via https://renaldrugdatabase.com Accessed 25/9/26.
- Sanford guide [online]. Cycloserine. Last updated 1/7/26. Accessed via https://webedition.sanfordguide.com Accessed 25/9/26.